These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
277 related articles for article (PubMed ID: 34528187)
1. Furmonertinib: First Approval. Deeks ED Drugs; 2021 Oct; 81(15):1775-1780. PubMed ID: 34528187 [TBL] [Abstract][Full Text] [Related]
2. Efficacy, safety, and genetic analysis of furmonertinib (AST2818) in patients with EGFR T790M mutated non-small-cell lung cancer: a phase 2b, multicentre, single-arm, open-label study. Shi Y; Hu X; Zhang S; Lv D; Wu L; Yu Q; Zhang Y; Liu L; Wang X; Cheng Y; Ma Z; Niu H; Wang D; Feng J; Huang C; Liu C; Zhao H; Li J; Zhang X; Jiang Y; Gu C Lancet Respir Med; 2021 Aug; 9(8):829-839. PubMed ID: 33780662 [TBL] [Abstract][Full Text] [Related]
3. Furmonertinib (AST2818) versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer (FURLONG): a multicentre, double-blind, randomised phase 3 study. Shi Y; Chen G; Wang X; Liu Y; Wu L; Hao Y; Liu C; Zhu S; Zhang X; Li Y; Liu J; Cao L; Cheng Y; Zhao H; Zhang S; Zang A; Cui J; Feng J; Yang N; Liu F; Jiang Y; Gu C; Lancet Respir Med; 2022 Nov; 10(11):1019-1028. PubMed ID: 35662408 [TBL] [Abstract][Full Text] [Related]
4. Lazertinib: First Approval. Dhillon S Drugs; 2021 Jun; 81(9):1107-1113. PubMed ID: 34028784 [TBL] [Abstract][Full Text] [Related]
5. First report of furmonertinib as a first-line treatment in advanced lung adenocarcinoma patients harboring EGFR exon 20 insertion mutations after the kinase domain αC-helix: Two case reports and a literature review. Han H; Zhang X; Liu X; Zhao J; Zhang J; Zhang J; Zhu H; Jiao S; Tang H Medicine (Baltimore); 2023 Dec; 102(52):e36667. PubMed ID: 38206746 [TBL] [Abstract][Full Text] [Related]
6. [First-line Treatment with Furmonertinib Mesylate in Lung Adenocarcinoma Patient with EGFR Exon 20 Insertion Mutantion]. Li Z; Wei T; Zeng D; Zhao L; Zhang J; Chen L Zhongguo Fei Ai Za Zhi; 2024 Mar; 27(3):241-244. PubMed ID: 38590198 [TBL] [Abstract][Full Text] [Related]
7. Central nervous system efficacy of furmonertinib (AST2818) in patients with EGFR T790M mutated non-small cell lung cancer: a pooled analysis from two phase 2 studies. Hu X; Zhang S; Ma Z; Feng J; Wu L; Lv D; Zhou J; Zhang X; Liu L; Yu Q; Liao W; Zhang Y; Wang X; Cheng Y; Niu H; Wang Z; Wang D; Huang C; Liu C; Zhao H; Feng J; Li J; Ying K; Yang N; Qin S; Hu J; Liu F; Jiang Y; Ge N; Shi Y BMC Med; 2023 Apr; 21(1):164. PubMed ID: 37118803 [TBL] [Abstract][Full Text] [Related]
8. A real-world study of the efficacy and safety of furmonertinib for patients with non-small cell lung cancer with EGFR exon 20 insertion mutations. Sa H; Shi Y; Ding C; Ma K J Cancer Res Clin Oncol; 2023 Aug; 149(10):7729-7742. PubMed ID: 37004599 [TBL] [Abstract][Full Text] [Related]
9. Befotertinib: First Approval. Blair HA Drugs; 2023 Oct; 83(15):1433-1437. PubMed ID: 37751131 [TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of re-challenging 160 mg furmonertinib for advanced NSCLC after resistance to third-generation EGFR-TKIs targeted agents: A real-world study. Qi R; Fu X; Yu Y; Xu H; Shen M; He S; Lv D Lung Cancer; 2023 Oct; 184():107346. PubMed ID: 37604026 [TBL] [Abstract][Full Text] [Related]
11. Three Third-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer: Similarities and Differences. Chen L; Zhou Y; Gan C; Wang X; Liu Y; Dong C; He R; Yang J Cancer Invest; 2022 Aug; 40(7):590-603. PubMed ID: 35445633 [TBL] [Abstract][Full Text] [Related]
12. Observational Study of Treatment Patterns in Patients with Epidermal Growth Factor Receptor (EGFR) Mutation-Positive Non-Small Cell Lung Cancer After First-Line EGFR-Tyrosine Kinase Inhibitors. Nadler E; Pavilack M; Espirito JL; Clark J; Fernandes A Adv Ther; 2020 Feb; 37(2):946-954. PubMed ID: 31955357 [TBL] [Abstract][Full Text] [Related]
13. Analysis of resistance mechanisms to abivertinib, a third-generation EGFR tyrosine kinase inhibitor, in patients with EGFR T790M-positive non-small cell lung cancer from a phase I trial. Zhang YC; Chen ZH; Zhang XC; Xu CR; Yan HH; Xie Z; Chuai SK; Ye JY; Han-Zhang H; Zhang Z; Bai XY; Su J; Gan B; Yang JJ; Li WF; Tang W; Luo FR; Xu X; Wu YL; Zhou Q EBioMedicine; 2019 May; 43():180-187. PubMed ID: 31027916 [TBL] [Abstract][Full Text] [Related]
14. Olmutinib: First Global Approval. Kim ES Drugs; 2016 Jul; 76(11):1153-7. PubMed ID: 27357069 [TBL] [Abstract][Full Text] [Related]
15. Successful salvage therapy using high-dose furmonertinib (AST2818) for non-small-cell lung cancer after Osimertinib resistance: a case report. Cheng D; Tang S; Li D; Zhao W; Wei W; Fang C; Ji M Anticancer Drugs; 2022 Sep; 33(8):768-772. PubMed ID: 35946524 [TBL] [Abstract][Full Text] [Related]
16. An evaluation of aumolertinib for the treatment of EGFR T790M mutation-positive non-small cell lung cancer. Wang J; Wu L Expert Opin Pharmacother; 2022 Apr; 23(6):647-652. PubMed ID: 35272542 [TBL] [Abstract][Full Text] [Related]
17. Mobocertinib: Mechanism of action, clinical, and translational science. Hanley MJ; Camidge DR; Fram RJ; Gupta N Clin Transl Sci; 2024 Mar; 17(3):e13766. PubMed ID: 38511563 [TBL] [Abstract][Full Text] [Related]
18. Safety, tolerability, and anti-tumor activity of olmutinib in non-small cell lung cancer with T790M mutation: A single arm, open label, phase 1/2 trial. Kim DW; Lee DH; Han JY; Lee J; Cho BC; Kang JH; Lee KH; Cho EK; Kim JS; Min YJ; Cho JY; An HJ; Kim HG; Lee KH; Kim BS; Jang IJ; Yoon S; Han O; Noh YS; Hong KY; Park K Lung Cancer; 2019 Sep; 135():66-72. PubMed ID: 31447004 [TBL] [Abstract][Full Text] [Related]
19. Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC). Gelatti ACZ; Drilon A; Santini FC Lung Cancer; 2019 Nov; 137():113-122. PubMed ID: 31568888 [TBL] [Abstract][Full Text] [Related]
20. Central Nervous System Efficacy of Furmonertinib (AST2818) Versus Gefitinib as First-Line Treatment for EGFR-Mutated NSCLC: Results From the FURLONG Study. Shi Y; Chen G; Wang X; Liu Y; Wu L; Hao Y; Liu C; Zhu S; Zhang X; Li Y; Liu J; Cao L; Cheng Y; Zhao H; Zhang S; Zang A; Cui J; Feng J; Yang N; Liu F; Jiang Y; Gu C J Thorac Oncol; 2022 Nov; 17(11):1297-1305. PubMed ID: 35932953 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]